Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Sosman JA, Atkins MB, Leming PD et al (2019) Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol 5(10):1411–1420. https://doi.org/10.1001/jamaoncol.2019.2187
Article
PubMed Central
Google Scholar
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454. https://doi.org/10.1056/NEJMoa1200690
CAS
Article
PubMed
PubMed Central
Google Scholar
Yoshino K, Nakayama T, Ito A, Sato E, Kitano S (2019) Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports. BMC Cancer 19:1019. https://doi.org/10.1186/s12885-019-6138-7
CAS
Article
PubMed
PubMed Central
Google Scholar
Gupta A, De Felice KM, Loftus EV Jr, Khanna S (2015) Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 42:406–417. https://doi.org/10.1111/apt.13281
CAS
Article
PubMed
Google Scholar
Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D et al (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24:2283–2289. https://doi.org/10.1200/jco.2005.04.5716
CAS
Article
PubMed
PubMed Central
Google Scholar
Canete F, Manosa M, Lobaton T, Mesonero F, Rodriguez-Lago I, Cabre E, Cabriada JL, Lopez-Sanroman A, Domenech E (2019) Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike-report of new cases and review of the literature. Int J Colorectal Dis 34:861–865. https://doi.org/10.1007/s00384-019-03268-4
Article
PubMed
Google Scholar
Yamauchi R, Araki T, Mitsuyama K, Tokito T, Ishii H, Yoshioka S, Kuwaki K, Mori A, Yoshimura T, Tsuruta O et al (2018) The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review. BMC Gastroenterol 18:135. https://doi.org/10.1186/s12876-018-0864-1
CAS
Article
PubMed
PubMed Central
Google Scholar
Thompson JA, Schneider BJ, Brahmer J, Armand P, Davies M, Ernstoff MS, Sosman JA, Johnson-Chilla A, Zuccarino-Catania G, Engh A (2020) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), management of immunotherapy-related toxicities, Version 1. J Natl Compr Canc Ne 18:231–241
Google Scholar
Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, Bresalier RS, Charabaty A, Dadu R, Jazaeri A et al (2019) Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer 7:93. https://doi.org/10.1186/s40425-019-0577-1
Article
PubMed
PubMed Central
Google Scholar
Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M (2019) Concurrent therapy with immune checkpoint inhibitors and TNFalpha blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer 7:226. https://doi.org/10.1186/s40425-019-0711-0
Article
PubMed
PubMed Central
Google Scholar
Shi HY, Chan FK, Leung WK, Li MK, Leung CM, Sze SF, Ching JY, Lo FH, Tsang SW, Shan EH et al (2016) Natural history of elderly-onset ulcerative colitis: results from a territory-wide inflammatory bowel disease registry. J Crohns Colitis 10:176–185. https://doi.org/10.1093/ecco-jcc/jjv194
Article
PubMed
Google Scholar
Ananthakrishnan AN, McGinley EL, Binion DG (2009) Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis 15:182–189. https://doi.org/10.1002/ibd.20628
Article
PubMed
Google Scholar
Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, Azimi R, Rizvi H, Riess JW, Hellmann MD et al (2018) Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol 36:1905–1912. https://doi.org/10.1200/jco.2017.77.0305
CAS
Article
PubMed
PubMed Central
Google Scholar
Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, Heinzerling L, Ugurel S, Pfohler C, Gesierich A et al (2017) Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 75:24–32. https://doi.org/10.1016/j.ejca.2016.12.038
CAS
Article
PubMed
Google Scholar
Schroeder KW, Tremaine WJ, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317:1625–1629. https://doi.org/10.1056/nejm198712243172603
CAS
Article
PubMed
Google Scholar
Common Terminology Criteria for Adverse Events(CTCAE), version 5.0. US Department of Health and Human Services, 2017. https://evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed 07 May, 2020.
Hijikata Y, Matsubara Y, Ota Y, Lim LA, Tani K, Hirata Y, Yotsuyanagi H (2020) Safe use of nivolumab in a patient with epipharyngeal carcinoma and preexisting ulcerative colitis: a histologically proven case report. Intern Med. https://doi.org/10.2169/internalmedicine.3901-19
Kahler KC, Eigentler TK, Gesierich A, Heinzerling L, Loquai C, Meier F, Meiss F, Pfohler C, Schlaak M, Terheyden P et al (2018) Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol Immunother 67:825–834. https://doi.org/10.1007/s00262-018-2134-z
CAS
Article
PubMed
Google Scholar
Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, Carneiro A, Marsal J (2017) Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother 66:581–592. https://doi.org/10.1007/s00262-017-1962-6
CAS
Article
PubMed
PubMed Central
Google Scholar
Bostwick AD, Salama AK, Hanks BA (2015) Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J Immunother Cancer 3:19. https://doi.org/10.1186/s40425-015-0064-2
Article
PubMed
PubMed Central
Google Scholar
Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, Collins M, Chaput N, Robert C, Carbonnel F et al (2018) Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut 67:2056–2067. https://doi.org/10.1136/gutjnl-2018-316948
CAS
Article
PubMed
Google Scholar
Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D’Inca R, Bossa F, Angelucci E, Biancone L, Gionchetti P et al (2011) Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 9:30–35. https://doi.org/10.1016/j.cgh.2010.09.026
CAS
Article
PubMed
Google Scholar
Ikeuchi H, Uchino M, Matsuoka H, Bando T, Hirata A, Takesue Y, Tomita N, Matsumoto T (2014) Prognosis following emergency surgery for ulcerative colitis in elderly patients. Surg Today 44:39–43. https://doi.org/10.1007/s00595-013-0563-z
Article
PubMed
Google Scholar
Karamchandani DM, Chetty R (2018) Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective. J Clin Pathol 71:665–671. https://doi.org/10.1136/jclinpath-2018-205143
CAS
Article
PubMed
Google Scholar
Yanai S, Nakamura S, Kawasaki K, Toya Y, Akasaka R, Oizumi T, Ishida K, Sugai T, Matsumoto T (2019) Immune checkpoint inhibitor-induced diarrhea: clinicopathological study of 11 patients. Dig Endosc. https://doi.org/10.1111/den.13555
Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ (2008) Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134:929–936. https://doi.org/10.1053/j.gastro.2008.01.012
Article
PubMed
Google Scholar
Sturm A, Maaser C, Mendall M, Karagiannis D, Karatzas P, Ipenburg N, Sebastian S, Rizzello F, Limdi J, Katsanos K et al (2017) European Crohn’s and Colitis Organisation topical review on IBD in the elderly. J Crohns Colitis 11:263–273. https://doi.org/10.1093/ecco-jcc/jjw188
Article
Google Scholar
Hiwatashi N, Suzuki Y, Mitsuyama K, Munakata A, Hibi T (2011) Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. J Gastroenterol 46:46–56. https://doi.org/10.1007/s00535-010-0308-3
CAS
Article
PubMed
Google Scholar
Ham M, Moss AC (2012) Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol 5:113–123. https://doi.org/10.1586/ecp.12.2
CAS
Article
PubMed
PubMed Central
Google Scholar
Kubo K, Kato M, Mabe K (2017) Nivolumab-associated colitis mimicking ulcerative colitis. Clin Gastroenterol Hepatol 15:A35–A36. https://doi.org/10.1016/j.cgh.2017.03.026
Article
PubMed
Google Scholar